Philippines - English - FDA (Food And Drug Administration)

n/a; importer: sandoz philippines corporation; distributor: the cathay yss distributors co., inc - memantine hydrochloride - film-coated tablet - 10 mg

Malta - English - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - amantadine sulfate - film-coated tablet - amantadine sulfate 100 mg - anti-parkinson drugs

Malta - English - Medicines Authority

janssen-cilag international nv turnhoutsewes 30, b-2340 beerse, belgium - galantamine - film-coated tablet - galantamine - psychoanaleptics

Malta - English - Medicines Authority

janssen-cilag international nv turnhoutsewes 30, b-2340 beerse, belgium - galantamine - film-coated tablet - galantamine - psychoanaleptics

Malta - English - Medicines Authority

janssen-cilag international nv turnhoutsewes 30, b-2340 beerse, belgium - galantamine - film-coated tablet - galantamine - psychoanaleptics

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - memantine hydrochloride 10 mg - eq. memantine 8,31 mg - film-coated tablet - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - memantine hydrochloride 10 mg - eq. memantine 8,31 mg - film-coated tablet - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - memantine

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population